Research use only, not for human consumption. Email [email protected]
← Research status explorer
Rebuild / Repair & longevity

SS-31

Also known as: Elamipretide, Forzinity

Current research status Approved Molecule*
Accelerated approval / confirmatory research ongoing
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*

Overview

SS-31 (elamipretide) is a mitochondria-targeted peptide. Under the brand name Forzinity, it received FDA accelerated approval on September 19, 2025 for improving muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg, based on an intermediate clinical endpoint. The FDA requires a post-approval confirmatory trial to verify clinical benefit. This approval is specific to the Forzinity product, its dosing, and the Barth syndrome indication — it is not a general safety or efficacy finding for elamipretide as a compound, and it is not an approval of any research-grade SS-31 product.

Key research

  • TAZPOWER trial Basis for accelerated approval; knee extensor muscle strength endpoint.

Last reviewed: September 2026

*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.